Skip to main content
SpringerLink
Log in

The relevance of dopaminergic level in nocturnal disability in Parkinson’s disease: implications of continuous dopaminergic stimulation at night to treat the symptoms

  • Neurology and Preclinical Neurological Studies - Review Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

Sleep problems are an under-emphasized cause of disability in Parkinson’s disease (PD). Difficult sleep maintenance (light and fragmented sleep) and difficulties in initiating sleep are often the earliest and the most frequent symptoms observed in PD patients. In fluctuating patients, nocturnal akinesia, dystonia, painful cramps, and parasomnias may aggravate nocturnal problems. Treatment of sleep problems can be complex and challenging for the physicians. Dopaminergic treatment may improve some of the nocturnal symptoms in PD. In this paper, the effect of drugs and technique that ensure a more continuous delivery of dopaminergic drugs on sleep problems in PD is reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Baas HK, Schueler P (2001) Efficacy of cabergoline in long-term use: results of three observational studies in 1500 patients with Parkinson’s disease. Eur Neurol 46(Suppl 1):18–23

    Article  CAS  PubMed  Google Scholar 

  • Barone P, Amboni M, Vitale C, Bonavita V (2004) Treatment of nocturnal disturbances and excessive daytime sleepiness in Parkinson’s disease. Neurology 63(8 Suppl 3):S35–S38

    Article  PubMed  Google Scholar 

  • Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649

    Article  PubMed  Google Scholar 

  • Chaudhuri KR, Clough C (1998) Subcutaneous apomorphine in Parkinson’s disease. BMJ 316(7132):641

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Chaudhuri KR, Logishetty K (2009) Dopamine receptor agonists and sleep disturbances in Parkinson’s disease. Parkinsonism Relat Disord 15(Suppl 4):S101–S104

    Article  PubMed  Google Scholar 

  • Christmas TJ, Kempster PA, Chapple CR, Frankel JP, Lees AJ, Stern GM, Milroy EJ (1988) Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 2(8626–8627):1451–1453

    Article  CAS  PubMed  Google Scholar 

  • Factor SA, Weiner WJ (1998) Sleep benefit in Parkinson’s disease. Neurology 50(5):1514–1515

    Article  CAS  PubMed  Google Scholar 

  • Factor S, McAlarney T, Sanchez-Ramos JR, Weiner WJ (1990) Sleep disorders and sleep effect in Parkinson’s disease. Mov Disord 5:280–285

    Article  CAS  PubMed  Google Scholar 

  • Fernandez HH, Odin P (2011) Levodopa–carbidopa intestinal gel for treatment of advanced Parkinson’s disease. Curr Med Res Opin 27(5):907–919

    Article  CAS  PubMed  Google Scholar 

  • Friedman A (1980) Sleep pattern in Parkinson’s disease. Acta Med Pol 21(2):193–199

    CAS  PubMed  Google Scholar 

  • Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S (1999) Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 10(52(9)):1908–1910

    Article  Google Scholar 

  • Garcia Ruiz PJ (2006) Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson’s disease. Mov Disord 21(5):727–728

    Article  PubMed  Google Scholar 

  • Ghys L, Surmann E, Whitesides J, Boroojerdi B (2011) Effect of rotigotine on sleep and quality of life in Parkinson’s disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline. Expert Opin Pharmacother 12(13):1985–1998

    Article  CAS  PubMed  Google Scholar 

  • Giladi N, Fichtner A, Poewe W, Boroojerdi B (2010) Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson’s disease. J Neural Transm 117(12):1395–1399

    Article  CAS  PubMed  Google Scholar 

  • Högl B, Rothdach A, Wetter TC, Trenkwalder C (2003) The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson’s disease. Neuropsychopharmacology 28(10):1866–1870

    Article  PubMed  Google Scholar 

  • Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K, Mancini F, Canesi M, Odin P, Chaudhuri KR (2009) Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24(10):1468–1474

    Article  PubMed  Google Scholar 

  • Jansen EN, Meerwaldtt JD (1990) Madopar HBS in nocturnal symptoms of Parkinson’s disease. Adv Neurol 53:527–531

    CAS  PubMed  Google Scholar 

  • Jellinger KA (1991) Pathology of Parkinson’s disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 14(3):153–197

    Article  CAS  PubMed  Google Scholar 

  • Johns MV (1993) Daytime sleepiness, snoring and obstructive sleep apnea. The Epworth Sleepiness Scale. Chest 103:30–36

    Article  CAS  PubMed  Google Scholar 

  • Kales AN, Phang JM (1971) The effect of divided calcium intake on calcium metabolism. J Clin Endocrinol Metab 32(1):83–87

    Article  CAS  PubMed  Google Scholar 

  • Kelly DD (1991) Disorders of sleep and consciousness. In: Kandel ER, Schwartz JH, Jessel TM (eds) Principles of neuronal science. Appleton and Lange, Norwalk, pp 805–819

    Google Scholar 

  • Leeman AL, O’Neill CJ, Nicholson PW, Deshmukh AA, Denham MJ, Royston JP, Dobbs RJ, Dobbs SM (1987) Parkinson’s disease in the elderly: response to an optimal spacing of night time dosing with levodopa. Br J Clin Pharmacol 24(5):637–643

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Lees AJ, Blackburn NA, Campbell VL (1988) The nighttime problems of Parkinson’s disease. Clin Neuropharm 11:512–519

    Article  CAS  Google Scholar 

  • Martinez-Martin P, Jeukens-Visser M, Lyons KE, Rodriguez-Blazquez C, Selai C, Siderowf A, Welsh M, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG, Schrag A (2011) Health-related quality-of-life scales in Parkinson’s disease: critique and recommendations. Mov Disord 26(13):2371–2380

    Article  PubMed  Google Scholar 

  • Pahwa R, Busenbark K, Huber SJ, Michalek D, Hubble JP, Koller WC (1993) Clinical experience with controlled-release carbidopa/levodopa in Parkinson’s disease. Neurology 43(4):677–681

    Article  CAS  PubMed  Google Scholar 

  • Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL, EASE-PD Adjunct Study Investigators (2007) Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68(14):1108–1115

    Article  CAS  PubMed  Google Scholar 

  • Pastor P, Tolosa E (2003) Cabergoline in the treatment of Parkinson’s disease. Neurologia 18(4):202–209

    CAS  PubMed  Google Scholar 

  • Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B, SP 515 Investigators (2007) Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6(6):513–520

    Article  CAS  PubMed  Google Scholar 

  • Priano L, Albani G, Brioschi A, Guastamacchia G, Calderoni S, Lopiano L, Rizzone M, Cavalli R, Gasco MR, Fraschini F, Bergamasco B, Mauro A (2003) Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment. Neurol Sci 24(3):207–208

    Article  CAS  PubMed  Google Scholar 

  • Ray Chaudhuri K, Martinez-Martin P, Rolfe KA, Cooper J, Rockett CB, Giorgi L, Ondo WG (2012) Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson’s disease. Eur J Neurol 19:105–113

    Article  CAS  PubMed  Google Scholar 

  • Reichmann H, Cooper J, Rolfe K, Martinez-Martin P (2011) Sleep duration and “on’ time during different periods of the day and night in patients with advanced Parkinson’s disease receiving adjunctive ropinirole prolonged release. Parkinsons Dis 2011:354760

    PubMed Central  PubMed  Google Scholar 

  • Reuter I, Ellis CM, Ray Chaudhuri K (1999) Nocturnal subcutaneous apomorphine infusion in Parkinson’s disease and restless legs syndrome. Acta Neurol Scand 100(3):163–167

    Article  CAS  PubMed  Google Scholar 

  • Rinne UK, Larsen JP, Siden A, Worm-Petersen J (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 51(5):1309–1314

    Article  CAS  PubMed  Google Scholar 

  • Sanford M, Scott LJ (2011) Rotigotine transdermal patch: a review of its use in the treatment of Parkinson’s disease. CNS Drugs 25(8):699–719

    Article  CAS  PubMed  Google Scholar 

  • Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C (2011) The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 26(Suppl 3):S42–S80

    Article  PubMed Central  PubMed  Google Scholar 

  • Stocchi F, Destée A (1998) Co-administration of ropinirole and domperidone during rapid dose escalation of the dopamine agonist. Parkinsonism Relat Disord 4(4):183–188

    Article  CAS  PubMed  Google Scholar 

  • Stocchi F, Ruggieri S, Baronti F, Bellantuono P, Brughita G, Antonini A, Bravi D, Agnoli A (1987) On-off phenomena in Parkinson’s disease. Continuous dopaminergic stimulation. Clin Ter 122(2):83–88

    CAS  PubMed  Google Scholar 

  • Stocchi F et al (2000) Sleep disturbances in Parkinson’s disease. Eur J Neurol 7(Suppl. 4):21–25

    Google Scholar 

  • Stocchi F, Vacca L, Valente M, Ruggieri S (2001) Sleep disorders in Parkinson’s disease. Adv Neurol 86:289–293

    CAS  PubMed  Google Scholar 

  • Tandberg E, Larsen JP, Karlsen K (1999) Excessive daytime sleepiness and sleep benefit in Parkinson’s disease: a community-based study. Mov Disord 14:922–927

    Article  CAS  PubMed  Google Scholar 

  • Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR, Recover Study Group (2011) Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26(1):90–99

    Article  PubMed Central  PubMed  Google Scholar 

  • Tribl GG, Sycha T, Kotzailias N, Zeitlhofer J, Auff E (2005) Apomorphine in idiopathic restless legs syndrome: an exploratory study. J Neurol Neurosurg Psychiatry 76(2):181–185

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Van den Kerchove M, Jacquy J, Gonce M, De Deyn PP (1993) Sustained-release levodopa in parkinsonian patients with nocturnal disabilities. Acta Neurol Belg 93(1):32–39

    PubMed  Google Scholar 

  • Wailke S, Herzog J, Witt K, Deuschl G, Volkmann J (2011) Effect of controlled-release levodopa on the microstructure of sleep in Parkinson’s disease. Eur J Neurol 18(4):590–596

    Article  CAS  PubMed  Google Scholar 

  • Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 356(1):39–46

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Research and Medical Care IRCCS San Raffaele, Via della Pisana 235, 00163, Rome, Italy

    Fabrizio Stocchi & Paola Stirpe

Authors
  1. Fabrizio Stocchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paola Stirpe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fabrizio Stocchi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stocchi, F., Stirpe, P. The relevance of dopaminergic level in nocturnal disability in Parkinson’s disease: implications of continuous dopaminergic stimulation at night to treat the symptoms. J Neural Transm 121 (Suppl 1), 79–83 (2014). https://doi.org/10.1007/s00702-014-1259-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-014-1259-2

Keywords

Search

Navigation